These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7956218)

  • 21. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
    Meriggiola MC; Bremner WJ; Costantino A; Di Cintio G; Flamigni C
    Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sperm motion parameters after suppression of spermatogenesis with a gonadotropin-releasing hormone antagonist plus testosterone supplementation.
    Bastias MC; Kamijo H; Pavlou SN
    Fertil Steril; 1993 Jun; 59(6):1261-5. PubMed ID: 8495775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute and chronic effects of a gonadotrophin-releasing hormone antagonist on pituitary and testicular function in monkeys.
    Bint Akhtar F; Weinbauer GF; Nieschlag E
    J Endocrinol; 1985 Mar; 104(3):345-54. PubMed ID: 3882872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential of mild testicular heating as a safe, effective and reversible contraceptive method for men.
    Mieusset R; Bujan L
    Int J Androl; 1994 Aug; 17(4):186-91. PubMed ID: 7995654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible physiological bases for contraceptive techniques in the male.
    Setchell BP
    Hum Reprod; 1994 Jun; 9(6):1081-7. PubMed ID: 7962380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of progesterone in DNA synthesis of pregnancy-dependent mammary tumors in mice.
    Yanai R; Nagasawa H
    Int J Cancer; 1976 Sep; 18(3):317-21. PubMed ID: 986372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral administration of an anti-inflammatory does not compromise the efficacy of intra-testicular injection of zinc gluconate as a contraceptive for dogs.
    Oliveira EC; Muller PM; Silva FL; Nery LT; de Sá MJ; Guerra MM; Oliveira-Esquerre KP; Kastelic JP; Douglas RH
    Anim Reprod Sci; 2012 Jun; 132(3-4):207-12. PubMed ID: 22682769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of testosterone enanthate on testis size.
    Palacios A; McClure RD; Campfield A; Swerdloff RS
    J Urol; 1981 Jul; 126(1):46-8. PubMed ID: 6788960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The combined use of oral medroxyprogesterone acetate and methyltestosterone in a male contraceptive trial programme.
    Bain J; Rachlis V; Robert E; Khait Z
    Contraception; 1980 Apr; 21(4):365-79. PubMed ID: 6771093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trials for development of once-a-month injectable, hormonal male contraceptive using dienogest plus testosterone undecanoate: dose standardization, efficacy and reversibility studies in rats.
    Misro MM; Chaki SP; Kaushik MC; Nandan D
    Contraception; 2009 Jun; 79(6):488-97. PubMed ID: 19442786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of intratesticular administration of zinc gluconate and dimethyl sulfoxide on clinical, endocrinological, and reproductive parameters in dogs.
    Vannucchi CI; Angrimani DS; Eyherabide AR; Mazzei CP; Lucio CF; Maiorka PC; Silva LC; Nichi M
    Theriogenology; 2015 Oct; 84(7):1103-10. PubMed ID: 26174036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of low-dosage oral cyproterone acetate as a male contraceptive.
    Wang C; Yeung KK
    Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is high dosage testosterone an effective male contraceptive agent?
    Matsumoto AM
    Fertil Steril; 1988 Aug; 50(2):324-8. PubMed ID: 3396702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antispermatogenic action of gossypol in men.
    Coutinho EM; Melo JF; Barbosa I; Segal SJ
    Fertil Steril; 1984 Sep; 42(3):424-30. PubMed ID: 6468676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The regulation of male fertility: the state of the art and future possibilities.
    de Krester DM
    Contraception; 1974 Jun; 9(6):561-600. PubMed ID: 4614937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversible inhibition of testicular function by a gonadotropin hormone-releasing hormone antagonist in monkeys (Macaca fascicularis).
    Weinbauer GF; Surmann FJ; Akhtar FB; Shah GV; Vickery BH; Nieschlag E
    Fertil Steril; 1984 Dec; 42(6):906-14. PubMed ID: 6389185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An examination of blood steroid and gonadotropin concentrations in relation to fertility status and testicular function in men.
    Pierrepoint CG; Jenkins BM; Wilson DW; Phillips MJ; Gow JG
    Fertil Steril; 1982 Oct; 38(4):465-70. PubMed ID: 6811340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.